March 6, 2003
GlaxoSmithKline Donates $10 Million
To Support Research At the University of Pennsylvania
School of Medicine
(March 6,
2003) -- GlaxoSmithKline (GSK) and the University of
Pennsylvania School of Medicine announced today that
GSK has provided Penn with an unrestricted grant of
$10 million to support academic research.
"We at GSK are fortunate that the Delaware
Valley, home to so many of our Research and Development
staff, is also home to such a leading academic research
center as the University of Pennsylvania," said Tachi
Yamada, MD, Chairman, Research and Development, GSK.
"We are hopeful that this grant will further the important
research being done at Penn and facilitate scientific
interchange between its scientists and our own. GSK
and Penn are working towards a shared goal - increasing
our understanding of human disease and finding new treatments
for the patients who need them."
"We are delighted to receive this grant
and look forward to exploring mutual scientific interests
of Penn and GSK," said Dr. Arthur H. Rubenstein,
Executive Vice President of the University of Pennsylvania
for the Health System and Dean of the School of Medicine.
"This generous grant will permit our researchers to
continue to aggressively pursue the translational nature
of our work - which seeks to transform knowledge gained
at the benchside into safe and effective therapies and
treatments that improve patient care."
Contacts:
Rebecca Harmon (215) 349-5660 rebecca.harmon@uphs.upenn.edu
Louise Dunn From U.S. 44-20-8047-5495
louise.a.dunn@gsk.com
Rick Koenig (610) 270 5546
rick.m.koenig@gsk.com
GlaxoSmithKline (GSK) is one of
the world's leading research-based pharmaceutical and
healthcare companies and is committed to improving the
quality of human life by enabling people to do more,
feel better and live longer. The 18,000 people working
in GSK's global R&D organization discover, develop,
register, and support the commercialization of prescription
medicines and vaccines for the treatment and prevention
of human disease. In 2002 GSK invested $4 billion in
research and development at more than 20 sites worldwide.
GSK has R&D facilities in Philadelphia, Upper Merion,
and Upper Providence, which employ 3,500 staff. GSK
is a major funder of academic research in the US, with
378 active collaborations between US universities and
GSK researchers. PENN Medicine is a $2.2 billion enterprise
dedicated to the related missions of medical education,
biomedical research, and quality patient care.
PENN Medicine consists of the University
of Pennsylvania School of Medicine (founded in 1765
as the nation's first medical school) and the University
of Pennsylvania Health System (created in 1993 as the
nation's first integrated academic health system). Today,
Penn's School of Medicine is ranked #4 in the nation
in U.S. News & World Report's most recent ranking of
top research-oriented medical schools; and ranked #2
in the nation for receipt of NIH research funds. It
supports 1400 full time faculty and 700 students, is
recognized world-wide for its superior education and
training of the next generation of physician/scientists
and leaders of academic medicine. Penn's Health System
consists of four wholly-owned hospitals (including its
flagship Hospital of the University of Pennsylvania,
rated one of the nation's top "Honor Roll" hospitals
by U.S. News & World Report); a faculty practice plan;
a primary-care provider network; three multispecialty
satellite facilities; and home healthcare, hospice and
long-term care.
# # #
.
|
